Aduro gets back on track with CRS-207 af­ter FDA lifts par­tial clin­i­cal hold

Just a month af­ter the FDA forced Aduro to halt en­rolling more pa­tients in stud­ies us­ing its can­cer vac­cine CRS-207, the Berke­ley, CA-based biotech says reg­u­la­tors have lift­ed the par­tial hold, giv­ing it a green light to re­sume pro­ceed­ing on plan.

The par­tial hold was in­sti­tut­ed af­ter a pa­tient test­ed pos­i­tive for Lis­te­ria. CRS-207 us­es reengi­neered Lis­te­ria mono­cy­to­genes — re­mov­ing genes in or­der to dis­arm the bac­te­ria — that ex­press mesothe­lin, spark­ing an im­mune re­sponse to a pro­tein con­cen­trat­ed on can­cer cells.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER